Sign In
Buy VTGN
$0.560
-0.0199 (-3.43%)
At Close: Jun 03, 2026
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy
01:00pm, Friday, 06'th Sep 2024
VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript
07:05pm, Tuesday, 13'th Aug 2024
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2025 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Prince
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates
06:30pm, Tuesday, 13'th Aug 2024
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.94 per share a year ago.
3 Stocks Under $15 That Could Make You a Millionaire
06:20am, Friday, 26'th Jul 2024
Lately, the stock market has been soaring thanks mostly to growth stocks trading at sky-high valuations. While rate cuts could potentially boost markets, caution is still warranted for most investors.
Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript
06:41pm, Tuesday, 11'th Jun 2024
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2024 Earnings Conference Call June 11, 2024 5:00 PM ET Company Participants Mark McPartland - Senior Vice President, Investor Relations Shawn Singh - Chie
Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
04:20pm, Tuesday, 11'th Jun 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking
Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
08:30am, Friday, 07'th Jun 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapi
Vistagen to Present at the Jefferies Global Healthcare Conference
08:30am, Wednesday, 29'th May 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapi
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
08:30am, Thursday, 23'rd May 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affec
3 Must-Have Penny Stocks to Boost Your 2024 Portfolio
06:59am, Tuesday, 14'th May 2024
Penny stocks can be super volatile, but the potential of a modest investment ballooning into a multi-bagger is tough to pass up. These stocks represent the riskier end of the public equity range.
Meme Stock Rebound: 3 Reddit Favorites Primed for a Resurgence
10:00am, Monday, 13'th May 2024
The hype train is always talking about meme stocks set for a rebound on Reddit (NASDAQ: RDDT ). I try my best to avoid these large echo chambers of misinformation.
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
08:30am, Tuesday, 07'th May 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals a
PRISM MarketView – Weekly Market Report – April 26, 2024
02:39pm, Friday, 26'th Apr 2024
PRISM Market Pulse: Equities Rally Amid Mixed Big Tech Earnings; Economic Shifts and Sector-Specific Highlights New York, N.Y., April 26, 2024 – PRISM MarketView – Equities were higher through th
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
08:30am, Thursday, 25'th Apr 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals a
7 Stocks Under $15 Predicted to Boom in the Next 2 Years
07:13am, Friday, 19'th Apr 2024
If you're searching for stocks under $15, look no further. These seven offerings, all priced below $15, present a unique opportunity for individual investors to profit from future development.
